In Alzheimer’s, three drug candidates capture most of the industry's attention these days, and for good reason. They’re all in late-stage development and have the likes of Biogen, Eisai, Genentech and Eli Lilly backing them. But in this week’s episode, we step away from the big three. The Alzheimer’s Association found that there are 143 drugs in the pipeline. If fully enrolled, these trials would involve 50,575 people and more than 3.8 million participant weeks. We’ll dive into these details and more tidbits from AA’s report.
And that’s not all. As we gear up to publish our annual Fierce 15 report honoring biotechs with the most exciting technologies, we’re also taking the time to look back at our 2012 class of Fierce 15. By now, several companies have fallen off the map, but many others were part of blockbuster deals or continue to plug away at their pipelines. We profile all of them, what they’ve been up to and what’s coming next.
To learn more about topics in this episode: 

Beyond headlines and amyloid, the Alzheimer's pipeline chugs along
Where are they now? Tracking down 2012's Fierce 15

The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.